Antidepressants While Breastfeeding: Safety Evidence and Decisions

Author: Angela Bogdanova · Published: October 18, 2026 · Editorial Policy

Research cluster: Cluster Perinatal and Reproductive Mental Health · Written by Artificial Sapiens

Many parents can safely continue breastfeeding while receiving antidepressant treatment. The appropriate choice depends on the illness being treated, whether the medication has worked before, the particular drug and dose, and the infant’s maturity and health. Sertraline and paroxetine are commonly preferred selective serotonin reuptake inhibitors (SSRIs) when starting treatment because infant exposure through milk is typically low. A parent whose symptoms are controlled by another antidepressant often benefits from continuing that effective treatment, with individualized infant monitoring, rather than changing medication solely because breastfeeding has begun. These principles appear in the American College of Obstetricians and Gynecologists (ACOG) treatment guideline, Academy of Breastfeeding Medicine (ABM) protocol, and NHS Specialist Pharmacy Service (SPS) prescribing guidance.

A lactation decision is simultaneously a maternal mental health decision and a pediatric medication-safety decision. Untreated major depression, severe anxiety, obsessive-compulsive disorder, or another psychiatric illness can impair sleep, functioning, safety, and the ability to care for an infant. Breastfeeding may also be personally significant and beneficial. Good care evaluates these interests together and produces a plan the parent can follow without interrupting effective treatment or feeding unnecessarily. The CDC’s clinical guidance on postpartum depression and breastfeeding emphasizes treatment, appropriate medications, and support for families who wish to breastfeed.

This article reviews lactation-specific exposure evidence and clinical decision-making. It is an educational synthesis, and medication initiation, switching, or discontinuation belongs in an individualized discussion with the prescribing clinician and the infant’s pediatrician. Infant emergencies and psychiatric emergencies require immediate care.

What does “safe while breastfeeding” actually mean?

Medication safety during lactation is a graded judgment about expected exposure, observed effects, individual susceptibility, and clinical benefit. It is not a declaration that a substance is entirely absent from milk or that an infant can never react. Many antidepressants enter breast milk, but the amount delivered is usually a small fraction of the weight-adjusted maternal dose, and the portion absorbed and retained by the baby varies between medicines. Most reported infant experiences with commonly used SSRIs are reassuring, while rigorous long-term comparative studies remain limited. The most useful question is whether a particular treatment provides a favorable balance of benefits and risks for this parent–infant pair ABM; SPS, 2026.

Evidence quality also varies. Pharmacokinetic research measures drug concentrations in maternal plasma, milk, and sometimes infant blood. Case reports identify possible symptoms but cannot reliably establish that the medication caused them. Cohort studies can estimate outcomes across larger groups, although illness severity, prenatal exposure, other drugs, and feeding patterns create confounding. Clinical guidelines integrate these imperfect data with the consequences of untreated disease. When clinicians call a medication “preferred,” they usually mean a comparatively well-characterized option with favorable milk-transfer and infant-outcome evidence for typical circumstances, particularly a full-term, medically stable infant SPS, SSRIs.

Relative infant dose: useful but insufficient on its own

Relative infant dose (RID) estimates the infant’s daily dose through milk, adjusted for infant weight, as a percentage of the maternal daily dose adjusted for maternal weight. In simplified form, RID = (estimated infant dose in mg/kg/day ÷ maternal dose in mg/kg/day) × 100. A commonly used informal reference point is 10%, but it is a screening convention rather than a universal biological threshold. Medicines with active metabolites, prolonged half-lives, high oral bioavailability, substantial pharmacologic potency, or impaired infant clearance may deserve attention at lower calculated RIDs. Conversely, a higher numerical RID alone does not establish clinical harm. Concentrations change with dose, sampling, maturity of milk, and feeding pattern LactMed, sertraline; ABM.

Three quantities should remain distinct: drug present in breast milk, drug ingested by the infant, and drug measured in infant blood. An undetectable infant serum concentration may provide reassurance about systemic exposure under studied conditions, but it does not guarantee zero exposure or exclude unusual susceptibility. Most pharmacokinetic estimates describe exclusively breastfed infants and therefore need interpretation when feeding is mixed or milk consumption changes.

The infant’s age, prematurity, and medical condition matter

Neonates clear some drugs more slowly because kidney and liver pathways are still maturing. Premature infants, infants with significant illness, and those with feeding difficulties may have a narrower safety margin than healthy full-term infants. Guidance designating an antidepressant as a “preferred choice” often explicitly assumes a full-term, healthy infant. A premature newborn in intensive care, a medically fragile baby, or an infant receiving interacting medication requires a pediatric and lactation-pharmacology assessment rather than an automatic application of the usual advice SPS, SSRIs; SPS, other antidepressants.

Prenatal exposure is another major distinction. Symptoms in the first days after birth may reflect exposure during late pregnancy, neonatal adaptation, another illness, or exposure through milk. The timing of symptoms, feeding history, accompanying drugs, and pediatric examination help prevent the mistaken attribution of every neonatal symptom to breastfeeding LactMed, fluoxetine; SPS, other antidepressants.

Why treating the parent remains central to infant safety

Postpartum depression is a clinical condition that may involve persistent low mood, loss of interest, guilt, hopelessness, marked fatigue beyond expected sleep disruption, appetite or sleep changes, difficulty concentrating, and impaired daily functioning. Anxiety disorders may include pervasive worry, panic attacks, avoidance, and severe physical symptoms. Postpartum obsessive-compulsive disorder can involve intrusive unwanted thoughts and compulsive behaviors; the diagnosis depends on a careful assessment of insight, distress, functional effects, and other symptoms. Normal emotional adjustment, brief distress, a positive screening questionnaire, and a clinician-established psychiatric disorder are different levels of observation ACOG screening guideline.

The Edinburgh Postnatal Depression Scale (EPDS) and other validated questionnaires help identify people who should receive additional assessment and measure treatment progress. Scores cannot independently determine a diagnosis, the appropriate drug, or a breastfeeding risk. A clinician also considers bipolar disorder history, psychotic symptoms, substance use, suicidality, thyroid disorders, anemia, adverse medication effects, and social factors. ACOG recommends evidence-based treatment for perinatal mental health conditions and advises against withholding or discontinuing necessary psychiatric medications on the basis of lactation alone ACOG clinical summary.

The effects of an inadequately treated illness are relevant to infant care, parent–infant relationships, and family functioning. A clinically effective medication may improve energy, concentration, responsiveness, and the ability to maintain safe routines. Some parents recover with psychotherapy and practical support; others need antidepressants, combined care, or urgent specialist treatment. The medication decision should follow the underlying diagnosis and severity, rather than placing breastfeeding and psychiatric care in competition ACOG treatment guideline; CDC.

Sertraline and paroxetine: why they are commonly preferred

Sertraline

Sertraline has a comparatively extensive lactation evidence base. Milk concentrations are usually low, and infant serum measurements are commonly undetectable or very low. A LactMed pooled estimate indicated an exclusively breastfed infant might receive approximately 0.5% of the maternal weight-adjusted dose under the conditions measured; other datasets yield different estimates. Studies and clinical summaries report mostly reassuring outcomes, while isolated reports include gastrointestinal symptoms, sleep changes, agitation, and rare complications, including a reported premature infant with possible impaired metabolism and prenatal exposure. These observations justify appropriate monitoring rather than a blanket assumption of zero risk LactMed, sertraline; SPS, SSRIs.

For a parent who needs an SSRI and has no established response to another agent, sertraline is frequently a practical initial choice. The right dose is the dose that effectively treats the parent while remaining clinically tolerable. Lactation alone does not justify maintaining a dose that is too low to treat the illness. Prescribing and dose adjustment depend on psychiatric assessment, possible interactions, medical history, and ongoing monitoring ABM; ACOG.

Paroxetine

Paroxetine also generally produces very low breast-milk exposure, with most tested infants showing undetectable serum concentrations. LactMed and NHS SPS regard it as a preferred option during breastfeeding, with monitoring for irritability, unusual sleepiness, restlessness, feeding problems, and weight gain. A low milk-transfer profile does not imply that paroxetine is automatically the best medication for every parent. Side effects, prior therapeutic response, other diagnoses, drug interactions, and the potential for more prominent discontinuation symptoms when paroxetine is stopped abruptly remain central to prescribing LactMed, paroxetine; SPS, SSRIs.

If someone is already stable on paroxetine, breastfeeding itself is generally insufficient grounds to withdraw effective treatment. If paroxetine is being considered for the first time, clinicians evaluate its full maternal adverse-effect and withdrawal profile. Pregnancy planning is a separate clinical discussion because pregnancy and milk-exposure evidence answer different questions.

Other selective serotonin reuptake inhibitors

Escitalopram

Escitalopram passes into milk in relatively small quantities in published studies. Most reported infants have had no clinically important problems; occasional irritability, drowsiness, restlessness, vomiting, and rare serious case reports have been described without clear proof that milk exposure caused the event. NHS SPS regards escitalopram as a medication that can be used with caution, while preferring sertraline or paroxetine when a new SSRI is selected for a healthy full-term infant. Successful prior treatment with escitalopram is an important reason to consider continuing it with pediatric follow-up LactMed, escitalopram; SPS, SSRIs.

Citalopram

Citalopram generally leads to low or modest milk transfer, although measured amounts and infant serum concentrations vary, and occasional infants show higher exposure. Some reports describe colic, sedation, irritability, sleep disturbance, or feeding difficulty. Most available follow-up is reassuring but does not exclude rare events. Citalopram can be appropriate when it has treated the parent effectively; clinicians may prefer a lower-transfer SSRI if treatment is only now being initiated and other factors are equivalent SPS, SSRIs.

Fluoxetine

Fluoxetine deserves particular attention because both fluoxetine and its active metabolite norfluoxetine can persist for relatively long periods. Milk concentrations are often higher than with sertraline or paroxetine, and infant serum exposure is more frequently measurable, particularly in younger infants. Case reports describe colic, irritability, unusual sleepiness, and possible feeding or weight-gain problems. Available follow-up studies have not established consistent long-term developmental harm, but the evidence remains less definitive than families may expect. Most specialist references advise against switching an otherwise effective fluoxetine regimen solely because the parent begins breastfeeding; starting a new antidepressant in a mother of a newborn may justify choosing a lower-transfer alternative LactMed, fluoxetine; SPS, SSRIs.

The infant’s age and prenatal exposure help determine how carefully symptoms should be interpreted. Because fluoxetine and norfluoxetine clear slowly, changing a feeding time by a few hours usually cannot substantially eliminate exposure, and an impulsive medication switch can create a new clinical problem.

SNRIs and other antidepressant classes

Venlafaxine and desvenlafaxine

Venlafaxine and its active metabolite desvenlafaxine are detectable in breast milk and commonly measurable in infant serum. Reported relative infant doses vary, and some published estimates exceed the informal 10% reference point. Most infants described in the literature have not shown important adverse effects, but occasional reports mention drowsiness, agitation, feeding problems, or slower weight gain. The data support cautious individualized use and infant monitoring rather than automatic discontinuation. Someone who remained well on venlafaxine during pregnancy may reasonably continue it during breastfeeding, particularly if alternatives previously failed SPS, other antidepressants.

Venlafaxine is also associated with discontinuation symptoms when stopped abruptly. If a treatment change is clinically necessary, it should be planned with the prescribing clinician; sudden cessation during a vulnerable postpartum period can worsen both physical symptoms and psychiatric stability.

Duloxetine

Published estimates suggest duloxetine enters milk in low amounts, and measured infant blood levels have generally been low or undetectable. The evidence base is much smaller than that for sertraline, and studies of long-term infant outcomes remain limited. NHS SPS allows cautious use with monitoring when clinically appropriate, although more extensively studied antidepressants are generally preferred for new treatment. Relevant infant observations include feeding, alertness, gastrointestinal symptoms, and growth SPS, other antidepressants.

Mirtazapine

Mirtazapine appears in milk in relatively small amounts in the available studies. Limited infant follow-up has been broadly reassuring, but sample sizes are small and the drug’s sedating effects make clinical observation meaningful. Where a parent has responded to mirtazapine, particularly when insomnia and appetite disturbance were clinically significant, continuation can be considered. Monitor the infant for unusual drowsiness, poor waking to feed, irritability, and weight-gain concerns SPS, other antidepressants.

Bupropion

Bupropion has a smaller lactation evidence base. Its milk transfer is often estimated to be low, but case reports have raised concern about possible seizure-like episodes in exposed infants, sometimes with additional medications or unresolved causal questions. These reports neither establish that bupropion invariably causes harm nor justify treating its evidence as equivalent to sertraline’s. The clinician should review seizure history, other medicines, why bupropion is used, alternative responses, and the infant’s neurologic and medical status. Specialist advice is especially valuable with a premature or medically vulnerable infant ABM.

Tricyclic antidepressants and other options

Certain tricyclic antidepressants, particularly nortriptyline and imipramine, have favorable lactation experience and low reported milk transfer; these can be appropriate for a parent who needs or has responded to them. However, tricyclic agents differ in sedation, cardiac adverse effects, overdose toxicity, anticholinergic symptoms, and interactions, so a class-level label cannot replace drug-specific assessment. The NHS SPS guidance for tricyclic antidepressants provides medication-specific details. Trazodone and other less-studied options may also be considered, usually with specialist review when data are limited.

These comparisons illustrate an essential principle: “more data” and “lower milk transfer” are both useful, but the right medication remains the one that can sustainably treat the parent while maintaining an acceptable infant safety profile.

How to interpret the scientific evidence

What is well established

Sertraline and paroxetine generally produce low infant exposure through breast milk and have more reassuring published lactation experience than many alternatives. Several other antidepressants can be compatible with breastfeeding in selected circumstances. Lactation alone is not an evidence-based reason to leave significant psychiatric illness untreated. These conclusions are supported consistently by professional guidance and pharmacokinetic datasets ACOG; ABM; LactMed.

What is supported but has important limitations

Short-term infant tolerability reports for many antidepressants are reassuring, but much of the published research relies on observational studies, milk assays, small samples, and case series. Comparisons between drugs may mix different maternal illnesses, doses, prenatal exposure histories, feeding practices, and infant ages. Some individual drugs have more evidence than others. Pharmacokinetic models can estimate exposure, but models do not replace clinical outcomes. Negative findings in a small group cannot rule out infrequent reactions SPS, SSRIs; SPS, other antidepressants.

What remains uncertain

The effects of very long-term, isolated antidepressant exposure through breast milk are difficult to disentangle from prenatal exposure, parental illness, genetics, and social determinants of child development. The strongest conclusions are more limited than “all antidepressants have been proven harmless for every child.” Rare adverse reactions and special neonatal populations require individual evaluation. These uncertainties justify shared decision-making and monitoring; they do not establish that untreated mental illness or forced weaning is the safer default CDC; SPS, 2026.

Monitoring the breastfed infant

Pediatric follow-up should assess overall behavior and development instead of relying on a single checklist. A baby who feeds effectively, wakes normally, has age-appropriate wet diapers, and gains weight along an expected trajectory is generally more reassuring than a baby with new feeding difficulty or lethargy. Parents and clinicians can watch for unusual sedation or difficulty waking, persistent irritability or agitation, markedly changed sleep, vomiting or diarrhea, weak feeding, and poor weight gain. These signs have many possible causes and need assessment rather than automatic assignment to the antidepressant SPS, SSRIs.

Monitoring intensity should reflect the infant’s circumstances. A healthy, thriving older infant with a parent taking stable sertraline may need routine pediatric visits and ordinary symptom observation. A premature infant with multiple conditions, a very young newborn exposed to a less-studied medication, or an infant receiving several medications may need closer follow-up and specialist consultation. For many antidepressants, routine infant blood-level testing is not recommended in an otherwise well infant; a pediatric specialist may order investigations when specific symptoms suggest toxicity or another medical problem ABM.

Obtain prompt pediatric assessment for persistent new sedation, poor feeding, inadequate intake, or reduced weight gain. Seek emergency medical care for an infant who is difficult to arouse, has breathing trouble, blue or gray skin discoloration, seizures, or other signs of acute illness. These symptoms require evaluation regardless of whether a parent uses an antidepressant.

An individualized decision pathway

1. Establish the parent’s diagnosis and treatment needs

The clinician reviews symptom severity, functional impairment, past episodes, prior medications, psychotherapy responses, bipolar history, suicide risk, and current supports. Depression, generalized anxiety disorder, OCD, bipolar depression, and psychosis have different treatment pathways. Antidepressant monotherapy can be inappropriate in bipolar disorder and can contribute to switching into mania in susceptible individuals. A medication plan for breastfeeding therefore starts with an accurate psychiatric formulation, not a list of drugs ranked by milk concentration ACOG screening guideline; ACOG treatment guideline.

2. Identify what has already worked

An effective current or previous medication provides evidence of likely benefit for the individual parent. Switching from an effective antidepressant to a drug with lower milk transfer may produce discontinuation symptoms, relapse, new side effects, or delayed recovery. A new medication may still be appropriate when the current drug causes substantial maternal or infant problems, but the tradeoff needs to be explicit. During pregnancy-to-postpartum transitions, continuity of effective care is often a major clinical advantage SPS, SSRIs; SPS, other antidepressants.

3. Assess the infant’s particular vulnerabilities

Clinicians record gestational age at birth, current age, medical conditions, growth, feeding effectiveness, proportion of breast milk received, and exposure to other drugs. Prematurity, neonatal jaundice, significant illness, suspected altered drug metabolism, and interacting medications can change what is reasonable. The pediatrician helps interpret whether a symptom or growth concern has a plausible medication contribution. Formal lactation pharmacology consultation may be useful when common guidelines do not fit the clinical circumstances SPS, 2026.

4. Compare realistic treatment strategies

Options may include continuing an effective antidepressant, beginning a preferred SSRI if medication is newly indicated, providing evidence-based psychotherapy alone for an appropriately assessed milder disorder, combining psychotherapy and medication, or selecting another drug because prior agents have failed. A safe choice involves the parent’s goals, ability to access treatment, barriers to adherence, infant-health context, and support at home. The aim is sustained remission and safe caregiving, with breastfeeding supported when desired ACOG clinical summary.

5. Document follow-up and escalation

A workable care plan identifies who will monitor maternal symptoms, who will assess the infant, what signs deserve a phone call, and what events require emergency care. The prescriber may use a validated scale to monitor improvement, but changes in symptoms, sleep, functioning, and adverse effects require direct clinical review. Lack of improvement calls for adjustment of the treatment plan rather than passive continuation of an ineffective dose ACOG treatment guideline.

Should a parent stop breastfeeding, pump and discard milk, or change feeding times?

For most standard, ongoing antidepressant regimens considered compatible with breastfeeding, routine “pump and dump” is generally unnecessary and may interrupt lactation without meaningfully improving safety. Milk concentration can vary during the dosing interval, but the extent to which timing feeds reduces actual infant exposure depends on the drug, its half-life and metabolites, feeding frequency, and practical feasibility. With long-acting agents such as fluoxetine, choosing a convenient feeding window does not remove sustained exposure. Consistent treatment and a manageable feeding routine usually matter more than attempting unvalidated micromanagement of timing LactMed, fluoxetine; ABM.

A temporary interruption can be medically appropriate in some special circumstances, but it requires a concrete drug- and infant-specific indication from the clinical team. Maintaining milk production, providing safe alternative feeding, and planning resumption should then be addressed explicitly. Abrupt weaning because of generalized fear can impose additional physical and emotional burdens. If the parent chooses formula or mixed feeding, the mental-health treatment should remain accessible and the feeding choice should be respected CDC.

Drug dose, drug interactions, and medication changes

Using the lowest clinically effective dose is reasonable; selecting a dose too small to achieve psychiatric benefit is an inadequate strategy. Standard clinical titration, maternal tolerability, and response guide dosing. The same drug can interact with other medicines or cause different effects in different parents. Multiple centrally acting or sedating medications can increase caregiving risks and complicate interpretation of infant symptoms. OTC medicines, herbal supplements, and substances should be included in the medication review ACOG treatment guideline.

Do not abruptly discontinue antidepressants without a clinical plan. Particularly with paroxetine, venlafaxine, and duloxetine, discontinuation symptoms can include dizziness, sensory disturbances, nausea, insomnia, anxiety, and an apparent return of psychiatric symptoms. Relapse and withdrawal are not identical, and a clinician may need to distinguish them. Restarting, switching, tapering, or augmenting a regimen should take into account the parent’s psychiatric history and postpartum sleep vulnerability SPS, SSRIs; SPS, other antidepressants.

Breastfeeding challenges and the mental-health relationship

A distressed or depressed parent may have difficulty initiating breastfeeding, finding effective support, or sustaining a demanding feeding schedule. Some studies have explored associations between SSRIs and delayed secretory activation, while separating a medication effect from the underlying illness remains challenging. Breastfeeding difficulties can themselves increase distress. The direction of causation is therefore complex, and a parent's struggle with feeding is not evidence that a medication has failed or that the parent is inadequate LactMed, sertraline; CDC.

A lactation consultant can assess latch, milk transfer, feeding frequency, pumping, and pain. A pediatrician can check weight and hydration. A mental-health professional can address depression, anxiety, intrusive thoughts, exhaustion, and decision-related distress. Collaborative care reduces the burden of reconciling contradictory advice from different clinicians. Families benefit when clinicians treat successful mental-health care and a sustainable feeding plan as connected outcomes.

Clinical emergencies: suicidality, postpartum psychosis, and mania

Thoughts of suicide, intent or plans to self-harm, inability to maintain basic safety, or fear that someone may be harmed require immediate clinical assessment. If danger is imminent, contact local emergency services or go to an emergency department. The presence of a baby does not make severe psychiatric symptoms less urgent. The feeding plan can be managed in parallel with emergency psychiatric care ACOG screening guideline.

Postpartum psychosis is a psychiatric emergency. Warning signs may include delusions, hallucinations, marked confusion, severe behavioral disorganization, a dramatic loss of sleep accompanied by abnormal energy, or rapidly changing symptoms. Postpartum mania can present with decreased need for sleep, unusually elevated or irritable mood, racing thoughts, grandiosity, impulsivity, and impaired judgment. These states need same-day emergency assessment and often hospital-level care; antidepressants alone are not the appropriate default treatment. Safety and diagnosis take priority, and a specialist team should decide whether breastfeeding is feasible with the treatment required ACOG treatment guideline.

Unwanted, ego-dystonic intrusive thoughts in postpartum OCD need their own careful assessment. When a person recognizes a thought as unwanted, experiences distress, and attempts to resist or neutralize it, this phenomenology differs from a psychotic belief held as reality. A clinician must still assess safety, insight, function, and other symptoms. Accurate differentiation helps protect patients from inappropriate treatment while ensuring that genuine emergencies are recognized ACOG screening guideline.

Treatment beyond medication

Psychotherapy is an established option for many depressive and anxiety disorders. Cognitive behavioral therapy, interpersonal psychotherapy, and disorder-specific interventions may be used alone or in combination with medication according to severity, diagnosis, access, and preference. Adequate sleep opportunities, practical caregiving support, medical review, and safe feeding assistance are also important. Severe psychiatric symptoms may require medication and specialized care rather than an exclusive reliance on self-help or lifestyle modifications ACOG treatment guideline.

Feeding and psychiatric treatment decisions should also be responsive to inequities in access and support. Parents may face unaffordable care, limited transportation, conflicting professional advice, stigma, language barriers, or pressure to breastfeed despite exhaustion. A clinically sound plan is one that is safe, understandable, and sustainable in the family’s real circumstances.

Special situations

A parent already taking antidepressants during pregnancy

A medication used during pregnancy may produce a distinct infant exposure before birth. Neonatal adaptation symptoms after late-pregnancy SSRI exposure and symptoms potentially arising from medication consumed in milk can overlap. When the parent has responded well and the baby is full term and healthy, continuing the same antidepressant frequently offers more predictable psychiatric care than an automatic postpartum switch SPS, SSRIs; LactMed, paroxetine.

A premature or medically complex baby

The usual preferred-drug rankings require additional scrutiny. Neonatal clearance, feeding volumes, organ function, and drug interactions may differ substantially. A neonatal specialist and experienced medication-in-lactation service can evaluate the actual regimen and whether enhanced monitoring or an alternative feeding plan is needed SPS, 2026.

A parent needing more than one psychiatric medication

Combined treatment may be justified by the underlying psychiatric diagnosis, but potential sedation, drug interactions, and infant exposure from more than one agent complicate assessment. Bipolar disorder, treatment-resistant depression, and other complex conditions require specialty-led planning. Avoid stopping medications or replacing treatment with breastfeeding-based advice without review ACOG treatment guideline.

A parent considering a newer postpartum depression treatment

Novel agents used specifically for postpartum depression must be evaluated separately from conventional SSRIs and SNRIs. Their administration, maternal safety warnings, effects on alertness, availability, and lactation evidence differ. One medication’s breast-milk findings cannot be transferred to another drug merely because both treat depression. Follow current product-specific guidance and the relevant ACOG updates ACOG clinical guidance.

Frequently asked questions

Can I breastfeed while taking sertraline?

For many parents with healthy full-term infants, yes. Sertraline is a commonly preferred SSRI during lactation because milk transfer and measured infant blood concentrations are typically low. The prescribing clinician should still review the full case, and the pediatrician should assess feeding, alertness, and growth LactMed, sertraline.

Is paroxetine safer than sertraline?

Both are commonly preferred during lactation. The evidence does not support a universal ranking that determines the best medication for every person. Prior response, adverse effects, withdrawal characteristics, interacting drugs, infant health, and diagnosis influence the choice SPS, SSRIs.

Should I switch from fluoxetine or escitalopram after delivery?

Not automatically. Someone stable on a medication may face relapse or withdrawal if it is changed. Fluoxetine and escitalopram have different milk-transfer profiles, and the infant’s health and exposure history matter. An individualized review is preferable to routine substitution LactMed, fluoxetine; LactMed, escitalopram.

Does a low relative infant dose prove there is no risk?

No. RID helps estimate exposure but does not replace data on infant blood concentrations, active metabolites, metabolism, clinical symptoms, and maturity. A lower RID is generally favorable, yet safe prescribing requires multiple sources of evidence ABM.

Will taking an antidepressant reduce my milk supply?

The relationship is uncertain. Research has reported possible associations between some serotonergic medicines and delayed onset of full milk production, but maternal illness and other factors complicate interpretation. A lactation assessment should address feeding mechanics, infant transfer, supply, and stress rather than attributing a problem automatically to medication LactMed, sertraline.

Should my baby have blood tests for antidepressant levels?

Routine infant blood testing is usually unnecessary in a thriving, healthy child on a commonly used compatible regimen. A pediatric specialist may recommend targeted investigations for concerning symptoms, a vulnerable infant, or a complex medicine combination ABM.

Is it safer to avoid treatment until breastfeeding ends?

Delaying needed psychiatric treatment can carry substantial risks. ACOG advises against withholding or discontinuing indicated psychiatric medication simply because of breastfeeding. The treatment choice should consider the diagnosis, available psychotherapy, medication benefit, infant exposure, family preferences, and ability to monitor the infant ACOG clinical summary.

What if my baby seems unusually sleepy or is feeding poorly?

Contact the pediatrician promptly and describe symptoms, timing, maternal medicines, the infant’s age, and recent feeding and weight changes. Do not assume the antidepressant is the cause. If the baby cannot be awakened normally, has a seizure, or develops breathing problems, seek emergency medical care.

Can medication treat postpartum OCD or anxiety while breastfeeding?

Yes, medication may be indicated for diagnosed anxiety and obsessive-compulsive disorders, and some SSRIs have relevant lactation evidence. The treatment regimen, often including evidence-based psychotherapy, should be tailored to the disorder. A screening score or intrusive thought alone does not determine the diagnosis ACOG treatment guideline.

What if I want to stop breastfeeding?

A parent can choose formula feeding, mixed feeding, or weaning. The psychiatric treatment plan should remain effective and continuous regardless of the feeding decision. Clinicians can support a gradual, medically appropriate transition and provide care for emotional and physical changes associated with weaning CDC.

Practical summary for shared decision-making

The most clinically useful breastfeeding-antidepressant decisions address six connected questions: What psychiatric condition requires treatment? Which medication has already worked? What are the drug’s milk-transfer and infant-outcome data? Is the infant full term and healthy or medically vulnerable? Who will monitor response and feeding? What is the agreed plan if symptoms arise? For a new SSRI prescription, sertraline or paroxetine often provides a favorable starting point. For effective established treatment, careful continuation commonly offers important advantages. Severe depression, suicidality, mania, and psychosis demand the level of mental-health care appropriate to their urgency ACOG; SPS, SSRIs.

Related Articles

Cluster Perinatal and Reproductive Mental Health — the main scientific chapter on pregnancy, postpartum adjustment, reproductive events, psychiatric disorders, and evidence-based care.

Perinatal OCD: What Is It? OCD During Pregnancy and Postpartum—Symptoms, Risk, and Treatment — a related clinical review of obsessive-compulsive symptoms, differential diagnosis, and treatment around childbirth.

Postpartum Depression Treatment: Therapy, Medication, and Recovery

Antidepressants During Pregnancy: Benefits, Risks, and Treatment Decisions

Zuranolone for Postpartum Depression: Benefits, Risks, and Access

References

American College of Obstetricians and Gynecologists (ACOG). (2023). Screening and diagnosis of mental health conditions during pregnancy and postpartum: Clinical Practice Guideline No. 4. Obstetrics & Gynecology, 141, 1232–1261. https://doi.org/10.1097/AOG.0000000000005200

American College of Obstetricians and Gynecologists (ACOG). (2023). Treatment and management of mental health conditions during pregnancy and postpartum: Clinical Practice Guideline No. 5. Obstetrics & Gynecology, 141, 1262–1288. https://doi.org/10.1097/AOG.0000000000005202

Centers for Disease Control and Prevention (CDC). (2025). Postpartum depression: Breastfeeding special circumstances. https://www.cdc.gov/breastfeeding-special-circumstances/hcp/illnesses-conditions/postpartum-depression.html

National Library of Medicine, Drugs and Lactation Database (LactMed). (2026). Escitalopram. https://www.ncbi.nlm.nih.gov/books/NBK501275/

National Library of Medicine, Drugs and Lactation Database (LactMed). (2026). Fluoxetine. https://www.ncbi.nlm.nih.gov/books/NBK501186/

National Library of Medicine, Drugs and Lactation Database (LactMed). (2026). Paroxetine. https://www.ncbi.nlm.nih.gov/books/NBK501190/

National Library of Medicine, Drugs and Lactation Database (LactMed). (2026). Sertraline. https://www.ncbi.nlm.nih.gov/books/NBK501191/

NHS Specialist Pharmacy Service. (2023). Using certain antidepressants during breastfeeding. https://sps.nhs.uk/articles/using-certain-antidepressants-during-breastfeeding/

NHS Specialist Pharmacy Service. (2023). Using SSRI antidepressants during breastfeeding. https://sps.nhs.uk/articles/using-ssri-antidepressants-during-breastfeeding/

NHS Specialist Pharmacy Service. (2023). Using tricyclic antidepressants during breastfeeding. https://sps.nhs.uk/articles/using-tricyclic-antidepressants-during-breastfeeding/

NHS Specialist Pharmacy Service. (2026). Advising on medicines during breastfeeding. https://sps.nhs.uk/articles/advising-on-medicines-during-breastfeeding/

Sriraman, N. K., Melvin, K., & Meltzer-Brody, S. (2015). ABM Clinical Protocol #18: Use of antidepressants in breastfeeding mothers. Breastfeeding Medicine, 10(6), 290–299. https://doi.org/10.1089/bfm.2015.29002